Esophageal cancer
Conditions
Interventions
Observation group:None
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients must be =18 years old at diagnosis. 2. Histologically or cytologically-diagnosed esophageal cancers (including advanced or metastatic, locally advanced surgically resectable, locally advanced unresectable patients) between Jan 1, 2023 and Dec 31, 2023. 3. No prior treatment and received the first anti-tumor treatment for the corresponding disease during eligibility period in the corresponding selected site 4. Patients must have informed consent form (ICF) signed for the study or have conditions that are accepted by Institutional Review Board/Independent Ethics Committee (IRB/IEC) to waive ICF
Exclusion criteria
Exclusion criteria: 1. Patient with multiple primary cancers or esophagogastric junction adenocarcinoma or early-stage esophageal cancer (T1N0M0) as reported in EMR 2. Has had previous therapy for advanced/metastatic esophageal cancer. Subjects may have received prior neoadjuvant or adjuvant therapy in consideration of following: a. Assessment of disease progression should be confirmed by CT scan. In certain situations, clinical evidence of disease progression such as any new or worsening malignant effusion (documented by ultrasound) and confirmation by pathologic criteria (histology and/or cytology) may be acceptable for assessment. b. Treatment with curative intent, including neoadjuvant/adjuvant treatment, given as chemotherapy or chemoradiotherapy, using standard of care agents or definitive chemoradiation, will count as a line of therapy if disease progression occurs during treatment or within 6 months of cessation of treatment. c. Dose reduction and/or switching of one or more agents due to toxicity/intolerability as deemed clinically appropriate by the investigator will not constitute a new line of therapy. 3.The patient has participated in any investigational program/interventional clinical trial with interventions outside of routine clinical practice for anti-tumor purpose.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Initial treatment pattern; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinicopathological feature;Subsequent treatment pattern ;Initial treatment pattern changes compared with those in CHANNEL study;Patient characteristics associated with receipt of first-line immune checkpoint inhibitor ; | — |
Countries
China
Contacts
Public ContactLin Shen
Beijing Cancer Hospital
Outcome results
None listed